Natural extracellular matrix (ECM) represents an ideal biomaterial for tissue engineering and regenerative medicine approaches. For further functionalization, there is a need for specific addressable functional groups within this biomaterial. Metabolic glycoengineering (MGE) provides a technique to incorporate modified monosaccharide derivatives into the ECM during their assembly, which was shown by us earlier for the production of a modified fibroblast-derived dermal ECM. In this study, adipose-derived stem cells (ASCs) were treated with the azide-modified monosaccharide derivate 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine (Ac4GalNAz). Toxicity and viability assays after 24 h and 72 h incubation revealed high biocompatibility of Ac4GalNAz in contact with ASCs. The successful incorporation of the functional azide groups into the glycocalyx and the ECM of the ASCs was proven by conjugation with a fluorescent dye via a copper-catalyzed click reaction. Thus, Ac4GalNAz in combination with ASCs was confirmed to achieve an azidemodified ECM as a multifunctional biomaterial for further applications.
Introduction
The extracellular matrix (ECM) represents the natural environment of cells in an organism, wherein it is synthesized and assembled by tissue-specific cells. Next to native ECM, derived from decellularized mature tissues, cell-specific matrices can also be obtained from the in vitro culture of these cells. Varying with the specific tissue or cell source, the ECM contains variable amounts of collagens, other fibrous and nonfibrous proteins, proteoglycans and glycoproteins and exhibits different physical properties. Native and cell-derived ECMs are used and studied in a variety of applications as potential biomaterials such as cell-influencing coatings [1, 2] , hybrid scaffolding materials for tissue engineering [3, 4] , and bioinks [5, 6] . A wide range of potential applications requires the modification of the ECM with specific addressable functional groups. Chemical modification of ECM compounds is challenging as it might affect matrix integrity. To address these issues, metabolic glycoengineering (MGE) represents a promising tool. This method is based on the incorporation of chemically modified monosaccharide derivatives into the natural intra-and extracellular oligosaccharide structures of the cell by its natural metabolic pathways [7, 8] . These functionalities can subsequently be addressed by bioorthogonal chemical ligation reactions [9, 10] for tuning chemical and physical properties and for visualization of glycoconjugates. Previously, we employed MGE with the azide-modified monosaccharide derivate 1,3,4,6-tetra-Oacetyl-N-azidoacetylgalactosamine (Ac4GalNAz) to generate a human fibroblast-derived dermal ECM containing azide groups [11] that can be addressed by copper-catalyzed azidealkyne cycloaddition [12, 13] . For this functionalized ECM (clickECM) we could show that the composition and functionality of the ECM was not affected by the MGE procedure and the modification with azide groups [11] . Later, also Gutmann et al. reported a similar approach using the corresponding azide-modified glucosamine derivative [14] .
In this study, we aimed to prove whether the glycocalyx and ECM of adipose-derived stem cells (ASCs) can be modified with azide groups using Ac4GalNAz in MGE ( Figure  1 ). Generation of an azide-modified stem cell ECM would be very promising for a wide range of applications especially in tissue engineering and regenerative medicine by representing a stem cell niche material with tunable chemical and physical properties. Such a unique biomaterial cannot be achieved by decellularization of tissues, as the stem cell niches are very small in vivo and integrated in matured neighboring tissues. Therefore, azide-modified ECM of ASCs provides multiple opportunities of further functionalization and application.
Materials and Methods

Isolation and expansion of ASCs
ASCs were isolated from human tissue samples obtained from patients undergoing plastic surgery (Dr. Ziegler; Klinik Charlottenhaus, Stuttgart, Germany) as described before [15] . All research was carried out in accordance with the rules for investigation of human subjects as defined in the Declaration of Helsinki. Patients provided written agreement in compliance with the Landesärztekammer Baden-Württemberg (F-2012-078, for normal skin from elective surgeries). ASCs were initially seeded at a density of 5x10 3 cells cm -2 in serumfree MSC growth medium (PELOBiotech, #PB-C-MH-675-0511-XF) containing 5 % human platelet lysate.
Biocompatibility assay
The biocompatibility of Ac4GalNAz was evaluated by a lactate dehydrogenase (LDH) assay (TaKaRa Bio Inc. #630117) and a resazurin assay (Sigma Aldrich, #R7017). ASCs were treated with 100 µM Ac4GalNAz or phosphate buffered saline (PBS) for 24 h and 72 h. LDH assay was performed according to manufacturer's protocol with cell culture supernatant. For the resazurin assay, culture medium was changed to medium with resazurin salt (11 µg/mL) and incubated for 3 h at 37 °C and 5 % CO2.
Detection of incorporated azide groups
Incorporated azide-groups were detected via copper-catalyzed azide-alkyne cycloaddition using an alkyne-linked fluorophore as described by Ruff et al. [11] . Isolated paraformaldehyde-fixed ECM was stained according to the manufacturer's instructions. Cell nuclei were counterstained with 1 μg/mL 4',6-diamidino-2-phenylindole (DAPI, Serva Electrophoresis) in PBS for 10 min at RT. Fluorescence images (z-stacks) were taken using a Zeiss Axio Observer.
Statistics
All experiments were performed with cells from three different biological donors. Data was compared by a one-way analysis of variance and a Tukey post-hoc test using OriginPro 2018b.
Results and Discussion
Biocompatibility of Ac4GalNAz was proven by LDH and resazurin assay ( Figure 2 ). Control groups (Ctr) were incubated with PBS and absorption values were normalized to the control groups. LDH assay revealed no cytotoxic effects of Ac4GalNAz after 24 h and 72 h. Metabolization of resazurin salt was comparable for cells treated with Ac4GalNAz to the control group. Thus, resazurin assay revealed no significant influence of Ac4GalNAz on metabolic activity of ASCs. These results are in line with previous studies using fibroblasts [11] .
ECM of ASCs can be successfully isolated and harvested as thin sheet of protein network ( Fig. 3 A; i) or left as thin gellike film on the bottom of the petri dish ( Figure. 3 A; ii). Incorporation of azide-groups into the glycocalyx and ECM of ASCs was proven by reaction with fluorophore-linked alkyne. In the untreated control group, no specific fluorescence staining was observed ( Figure 3B ). The cells treated with Ac4GalNAz exhibited a high specific fluorescence staining of the incorporated azide-groups. It was shown that azide groups were successfully incorporated into the glycocalyx of the cells. Moreover, for ECM isolated from ASCs and thereafter treated with Ac4GalNAz, showed a specific fluorescence of stained azide groups. This confirmed the incorporation of Ac4GalNAz in the stem cell ECM. The azide groups were ubiquitously distributed in the glycocalyx and the ECM, comparable to the findings of Ruff et al. [11] 
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No negative impact on cell survival and metabolic activity of ASCs was detectable. Further, it was shown that stem cell ECM of ASCs can be successfully modified with azide groups, which can be further addressed by alkyne-groups via coppercatalyzed azide-alkyne cycloaddition. Based on these results, Ac4GalNAz may be considered a suitable azide-modified monosaccharide derivative to be used in MGE with ASCs. Thereby, this approach opens up a wide field of medical and material applications of ASC-derived ECM by yielding a multifunctional biomaterial with tuneable chemical and physical properties.
